Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06426628 · ClinicalTrials.gov registry record
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
A clinical trial of Lung Cancer and Pulmonary Nodule, Solitary, sponsored by Veracyte.
- Recruiting
- Registry status
- 2,400
- Enrollment target
- 20
- Study locations
NCT06426628: Recruiting study of Lung Cancer and Pulmonary Nodule, Solitary, sponsored by Veracyte.
NCT06426628 is a study of Lung Cancer and Pulmonary Nodule, Solitary that is actively recruiting participants, run by Veracyte. The registered enrollment target is 2,400 participants, above the 930-participant average among 409 other Lung Cancer trials with a reported enrollment target (158% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06426628, a study of Lung Cancer and Pulmonary Nodule, Solitary, is actively recruiting participants, sponsored by Veracyte.
- RECRUITING
- Registry status
- 2,400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule. The main questions it aims to answer are: * Does the use of the Percepta Nasal swab test reduce the number of invasive procedures in people with a low-risk result and whose nodule is benign? * Does the use of the Percepta Nasal swab test decrease the time to treatment in people with a high-risk result and whose nodule is cancer? Participants will be randomly assigned to either a group where the test result is provided to the physician (test arm) or to a group where the test result is not provided (control arm). Researchers will compare management of participants in the two groups.
Primary Outcome
Invasive diagnostic procedures performed in the diagnostic workup of newly identified nodules that are benign.
Conditions Studied
Study Locations (20)
Florida
- Bay Pines VA HCS - Bay Pines
- North Florida/South Georgia Veterans Health System - Gainesville
- Bruce W. Carter Miami VA Medical Center - Miami
- Orlando VA Healthcare System - Orlando
Connecticut
- Trinity Health Of New England - Hartford
- The Stamford Health/The Stamford Hospital - Stamford
Illinois
- Northwestern University - Chicago
- OSF Saint Francis Medical Center - Peoria
Kentucky
- Lexington VA Health Care System - Lexington
- Robley Rex VA Medical Center - Louisville
Missouri
- Saint Lukes Hospital - Kansas City
- Mercy Hospital - Springfield
New York
- University of Rochester Medical Center - Rochester
- Good Samaritan Cancer Center - West Islip
Kansas
- University of Kansas Medical Center - Kansas City
Louisiana
- Southeast Louisiana Veterans Health Care System - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,400 participants |
| Start Date | 2022-07-18 |
| Est. Completion | 2027-03-31 |
What NCT06426628 shows while recruiting
NCT06426628 is an observational study that tracks outcomes without assigning an intervention. Its 2,400 participants enrollment target places it among the larger protocols in the corpus, above the 930-participant average among 409 other Lung Cancer trials with a reported enrollment target (158% higher).
The record links to 2 conditions, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06426628 names 20 study sites across 12 states, led by Florida, Connecticut, Illinois.
Frequently Asked Questions
What is clinical trial NCT06426628 about?
NCT06426628 is a clinical study titled "Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier". The goal of this observational study is to learn how a physician uses the results of the Percepta® Nasal Swab test to manage people with a newly identified pulmonary nodule. The main questions it aims to answer are: * Does the use of the Percepta Nasal swab test reduce the number of invasive proce...
What is the current status of trial NCT06426628?
This trial is currently recruiting. The enrollment target is 2,400 participants. The study started on 2022-07-18. Estimated completion is 2027-03-31.
What conditions does trial NCT06426628 study?
This clinical trial studies the following conditions: Lung Cancer, Pulmonary Nodule, Solitary.
Who is sponsoring clinical trial NCT06426628?
This trial is sponsored by Veracyte, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06426628 being conducted?
This trial has 20 study locations across Connecticut, Florida, Illinois, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06426628's enrollment target sits among peer trials
2,400 24th of 409 higher than 386 of 409 other Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
RECRUITING
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05185440 · 2,400 participants · NA
Reducing Alcohol Involved Sexual Violence in Higher Education
- NCT05285527 · 2,400 participants · NA
MiSight 1 Day Safety Post-Approval Study
- NCT05738330 · 2,400 participants · NA
Symptom Monitoring in Hemodialysis
- NCT05833360 · 2,400 participants
Prospective Study of oncRNA Stratification of Cancer by Size and Stage
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI